ABSTRACT
Understanding the brain changes underlying cognitive dysfunction is a key priority in multiple sclerosis to improve monitoring and treatment of this debilitating symptom. Functional connectivity network changes are associated with cognitive dysfunction, but it is less well understood how changes in normal appearing white matter relate to cognitive symptoms. If white matter tracts share a similar network structure it would be expected that tracts within a network are similarly affected by MS pathology. In the present study, we used a tractometry approach to explore patterns of variance in diffusion metrics across white matter (WM) tracts. We investigated whether separate networks, based on normal variation or pathology, appear, and how this relates to neuropsychological test performance across cognitive domains. A sample of 102 relapsing-remitting MS patients and 27 healthy controls underwent MRI and neuropsychological testing. Tractography was performed on diffusion MRI data to extract 40 WM tracts and microstructural measures were extracted from each tract. Principal component analysis (PCA) was used to decompose metrics from all tracts to assess the presence of any co-variance structure among the tracts. Similarly, PCA was applied to cognitive test scores to identify the main cognitive domains. Finally, we assessed the ability of tract components to predict test performance across cognitive domains. We found that a single component which captured pathology across all tracts explained the most variance and that there was little evidence for separate, smaller network patterns of pathology. WM tract components were weak, but significant, predictors of cognitive function in MS. These findings highlight the need to investigate the relationship between the normal appearing white matter and cognitive impairment further and on a more granular level, to improve the understanding of the network structure of the brain in MS.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was funded by a research grant of the MS Society UK and a Medical Research Council Doctoral Training Partnership grant (MR/N013751/11).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the NHS South-West Ethics and the Cardiff and Vale University Health Board R&D committees.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The data described in this manuscript are not available in the public domain, as this would not comply with the institutional ethics approval for the project under which the data were acquired. Direct requests for pseudoanonymized data can be considered, and will be dependent on the agreement on an appropriate inter-departmental data transfer agreement that includes the conditions for sharing and re-use.
